Literature DB >> 15664157

Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM.

Benoit Pasquier1, Pierre Launay, Yutaka Kanamaru, Ivan C Moura, Séverine Pfirsch, Claude Ruffié, Dominique Hénin, Marc Benhamou, Marina Pretolani, Ulrich Blank, Renato C Monteiro.   

Abstract

Serum IgA is considered a discrete housekeeper of the immune system with multiple anti-inflammatory functions, whereas IgA-immune complexes mediate inflammatory responses. Here, we identify FcalphaRI as a molecular device that determines the nature of IgA responses. In the absence of sustained aggregation, receptor targeting by serum IgA or anti-FcalphaRI Fab inhibits activating responses of heterologous FcgammaR or FcepsilonRI. The inhibitory mechanism involves recruitment of tyrosine phosphatase SHP-1 to FcalphaRI and impairment of Syk, LAT, and ERK phosphorylation induced by FcepsilonRI engagement. SHP-1 recruitment is dependent on ERK. Conversely, sustained aggregation of FcalphaRI by multimeric ligands stimulates cell activation by recruiting high amounts of Syk and aborting SHP-1 binding. Both types of signals require the FcRgamma-ITAM motif. Anti-FcalphaRI Fab treatment suppresses manifestations of allergic asthma in FcalphaRI transgenic mice. These findings redefine FcalphaRI as a bifunctional inhibitory/activating receptor of the immune system that mediates both anti- and proinflammatory functions of IgA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15664157     DOI: 10.1016/j.immuni.2004.11.017

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  128 in total

1.  IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.

Authors:  James M Kelley; Paul A Monach; Chuanyi Ji; Yebin Zhou; Jianming Wu; Sumiaki Tanaka; Alfred D Mahr; Sharleen Johnson; Carol McAlear; David Cuthbertson; Simon Carette; John C Davis; Paul F Dellaripa; Gary S Hoffman; Nader Khalidi; Carol A Langford; Phillip Seo; E William St Clair; Ulrich Specks; John H Stone; Robert F Spiera; Steven R Ytterberg; Peter A Merkel; Jeffrey C Edberg; Robert P Kimberly
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-06       Impact factor: 11.205

Review 2.  Dysfunctions of the Iga system: a common link between intestinal and renal diseases.

Authors:  Christina Papista; Laureline Berthelot; Renato C Monteiro
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

Review 3.  Regulation of mucosal IgA responses: lessons from primary immunodeficiencies.

Authors:  Andrea Cerutti; Montserrat Cols; Maurizio Gentile; Linda Cassis; Carolina M Barra; Bing He; Irene Puga; Kang Chen
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

Review 4.  The role of IgA and IgA Fc receptors as anti-inflammatory agents.

Authors:  Renato C Monteiro
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

5.  Erythropoiesis lagging? pIgA1 steps in to assist Epo.

Authors:  Robert F Paulson
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 6.  Innate signaling networks in mucosal IgA class switching.

Authors:  Alejo Chorny; Irene Puga; Andrea Cerutti
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

7.  Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12.

Authors:  Jessica A Hamerman; Nadia K Tchao; Clifford A Lowell; Lewis L Lanier
Journal:  Nat Immunol       Date:  2005-05-15       Impact factor: 25.606

Review 8.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

Review 9.  Cross-regulation of signaling by ITAM-associated receptors.

Authors:  Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

Review 10.  The expanding roles of ITAM adapters FcRgamma and DAP12 in myeloid cells.

Authors:  Jessica A Hamerman; Minjian Ni; Justin R Killebrew; Ching-Liang Chu; Clifford A Lowell
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.